THE UBIQUITIN PROTEASOME SYSTEM
===============================

Protein homeostasis is essential for proper function of a cell; therefore both protein synthesis and degradation are tightly regulated. Although there is a complex interplay between the two systems, in general, there are two main machineries involved in protein degradation: autophagy and the ubiquitin proteasome system (UPS). Autophagy involves lysosomal degradation by the formation of intracellular vesicles (autophagosomes) and is subdivided in chaperone-mediated autophagy (CMA), microautophagy, and macroautophagy. In CMA, chaperone proteins bind specifically to a KFERQ domain in a cytosolic protein, afterward it is internalized and degraded. Microautophagy is the direct lysosomal digestion of cytoplasmic content, which is trapped by random invagination of the lysosomal membrane. Macroautophagy functions as bulk degradation of mainly long-lived proteins, protein aggregates and organelles, and involves autophagosome formation to isolate cytoplasmic proteins. The UPS selectively targets individual proteins, including short-lived, damaged or defectively folded proteins, which accounts for about 80--90% of all intracellular proteins ([@B113]; [@B75]).

The UPS consists of two key components: the ubiquitination system, which selects and targets proteins towards degradation by ubiquitinating them, and the proteasome, a multimeric protein complex that actually performs the degradation. Protein degradation is a tightly regulated process: before a protein is cleaved by the proteasome, an elaborate process of selection and targeting has taken place exerted by the ubiquitin (Ub) system. This system mediates the conjugation of Ub, a small 76-amino-acid-long modifier. Binding of Ub to the target protein takes place in a three-step reaction. First, Ub is linked to an Ub-activating enzyme (E1) in an ATP-dependent manner. Subsequently, the activated Ub is transferred to an E2 conjugating enzyme, followed by attachment of E2 to a specific E3 ubiquitin ligase enzyme that binds the target protein. Lastly, Ub is transferred by the E2 enzyme to the target protein (**Figure [1](#F1){ref-type="fig"}**). Ub itself can be ubiquitinated at one of its seven lysine residues, resulting in various polyubiquitin chain types that each has its own specific signal function. Regulation of protein degradation is also mediated by deubiquitinating enzymes (DUBs) that can reverse ubiquitination by removing Ub residues of mono- or polyubiquitinated proteins ([@B44]; [@B75]).

![**Scheme of the ubiquitin proteasome system.** Proteins are targeted for degradation by ubiquitination via E1, E2, and E3 enzymes. The proteasome recognizes and removes the ubiquitination signal, unfolds the protein and finally degrades it.](fnmol-07-00073-g001){#F1}

Polyubiquitinated proteins are generally degraded by the 26S proteasome, which consists of a barrel-shaped 20S core that is the actual protease and a 19S regulatory complex that recognizes and unfolds the ubiquitinated substrate (**Figure [1](#F1){ref-type="fig"}**). The 20S core consists of two rings of seven α subunits, flanking two rings of seven β subunits. Three of these seven β subunits are catalytically active, with a caspase-like (β1), trypsin-like (β2), or chymotrypsin-like (β5) activity that cleave after negatively charged, positively charged, and hydrophobic amino acids, respectively ([@B75]). The 19S regulatory complex recognizes and unfolds the ubiquitinated substrate and guides it into the 20S core. The 19S complex consists of 19 individual proteins, of which six are ATPases of the AAA family ([@B11]). Binding of ATP is necessary for assembly of the 20S core with the 19S cap, subsequently ATP hydrolysis is required for protein unfolding, while for the next steps, gate opening, translocation and degradation, only ATP binding is required ([@B126]).

Next to the 19S complex, also other regulatory proteasome activators (PA) exist, including 11S (PA28), PI31, and PA200, which bind the 20S core in an ATP-independent way ([@B75]). PA28αβ expression is induced upon secretion of interferon gamma (IFNγ) and plays a role in processing peptides for MHC class I antigen presentation ([@B110]; [@B124]). When PA28αβ binds to 20S core, the activities of all β-subunits are increased, which is probably due to an increased accessibility rather than alterations within the active sites themselves. In contrast to PA28αβ, the exact mechanism that PA28γ, which is only expressed in the nucleus, uses to exert its function is not known ([@B111]).

IFNγ not only induces different PA caps but also induces the expression and incorporation of the proteasomal immuno-subunits β1i (LMP2), β2i (Mecl-1), and β5i (LMP7) that substitute β1, β2, and β5, respectively. With this replacement, the chymotrypsin-like activity increases and the immunoproteasome shows an altered cleavage pattern, resulting in different peptides being generated that are subsequently presented by MHC class-I molecules to the cells of the immune system ([@B124]; [@B9]).

GLIAL CELLS
===========

Neuroglia were first described by the German pathologist Rudolf Virchow already more than 150 years ago. For a long time these cells were considered as nerve glue, a kind of connective tissue holding the brain together. In contrast to neurons, glia are not electrically excitable. This made it difficult to study these cells, and as a consequence, most neuroscientific research was focused on neuronal function. When sophisticated molecular tools became available which made it possible to study the physiology of glial cells, this has led to a change in the neurocentric view of neuroscientists. During the last decades, it has become evident that glial cells are essential for proper neuronal function, are actively involved in neuronal communication, and form the immune system of the brain. As diverse as different glial cells are in morphology and origin, as diverse they are likely in their function. They take care of the general homeostasis in the brain, insulate neurons, and protect against pathogenic invaders ([@B65]). The ratio between neurons and glia in the human central nervous system (CNS) is about 1:1, with oligodendrocytes being the most abundant type of glial cells (75.6%), followed by astrocytes (17.3%) and microglia (6.5%) in human male brains ([@B104]). Below, the most important glial cell types and their functions are described (**Figure [2](#F2){ref-type="fig"}**).

![**The role of various glial cells in the healthy and diseased CNS. (A)** In the healthy situation, astrocytes support neurons by filtering nutrients from the blood and modulating synapses, oligodendrocytes wrap axons in isolating myelin sheets and microglia scan the environment for dead cells or invading pathogens. **(B)** During reactive gliosis in neurodegenerative diseases, oligodendrocytes and astrocytes lose their normal support function. Astrocytes decrease glutamate uptake from the synapse, leading to excitotoxicity. Microglia become activated and phagocytize dead cells and start to secrete pro-inflammatory cytokines that activate astrocytes. Both reactive astrocytes and activated microglia upregulate immunoproteasome expression. In particular diseases, demyelination of the axons is observed due to oligodendrocyte dysfunction.](fnmol-07-00073-g002){#F2}

ASTROCYTES
----------

Astrocytes perform a variety of crucial tasks in the CNS. Similar to neurons, astrocytes are of ectodermal origin. During the first stages of embryogenesis, the first astrocyte precursor cells arise from neural stem cells. These radial glia function as neural progenitors and form the scaffold that is used by immature neurons to migrate toward their final location. In a later stage, these cells give rise to the progenitors of oligodendrocytes as well as to the different kinds of astrocytes in the brain. The astrocyte population is broad and heterogeneous and the classification of subtypes is in its initial stage. Astrocytes contact multiple blood vessels with their endfeet, and they connect to neighboring astrocytes via gap junctions. Besides, astrocytes envelope multiple synapses and fibrous astrocytes in the white matter contact several nodes of Ranvier, which are the small gaps in myelinated axons ([@B127]; [@B94]). Subventricular astrocyte-like cells are the stem cells in the brain. The progeny of these cells migrate through the rostral migratory stream into the olfactory bulb, and differentiate into interneurons. When isolated and brought in culture, they can differentiate in both neurons and glia thus exhibiting multipotent properties ([@B81]). These cells are even still present in aged brains, suggesting regenerative potential until late in life ([@B147]).

In the mature brain, astrocytes influence synaptic transmission directly by the release of gliotransmitters including glutamate, ATP, GABA, and [D]{.smallcaps}-serine, although it is not fully understood how the cells release these transmitters. Astrocytes also respond to neurotransmitters, which leads to a surge in calcium. Although astrocytes do have voltage-gated channels ([@B100]), they are not able to respond with an increase in calcium in a millisecond time scale. Hence, astrocytes play a modulatory role: they are likely to influence synaptic communication of the many neurons in their domain. Astrocytes can also regulate synaptic transmission by mediating homeostasis of ions, pH and (neuro)transmitters. A well-known function of astrocytes is uptake of glutamate from the synaptic cleft via glutamate transporter Glt-1. Moreover, astrocytes contain transporters for the neurotransmitters GABA and glycine, for K^+^ ions, bicarbonate, water and monocarboxylic acid ([@B127]). Recently, it has been shown that astrocytes are able to influence synapses also by synaptic pruning both in the developing and in the adult mouse brain. This phagocytosis of synapses is dependent on neuronal activity and is mediated via the Mertk and Megf10 pathways. Thus, astrocytes actively contribute to activity-dependent synapse elimination and CNS remodeling ([@B29]). Next to the phagocytosis of synapses, activated astrocytes are able to phagocytize amyloid β deposits *in vitro* and *in situ* ([@B154]).

Furthermore, astrocytes form a key compartment of the blood brain barrier (BBB); they are not only involved in induction and development of the BBB, they also regulate BBB permeability ([@B1]). Astrocytes are connecting the blood vessels with many neuronal perikarya, axons and synapses. Therefore, astrocytes are the ideal cells to make an important contribution to the energy supply of the brain; for example by taking up glucose from the blood via their glucose transporters.

In conclusion, astrocytes are a heterogeneous group of glial cells that exert numerous tasks essential for proper neuronal function. They are indispensable in neurodevelopment, synaptic communication and brain homeostasis. As a consequence, loss or change in astrocyte function can contribute to pathogenesis of neurodegenerative diseases. A clear example is the leukodystrophy Alexander's disease, which is caused by a mutation in the astrocyte specific gene GFAP that leads to astrocyte pathology and dysfunction ([@B20]; [@B129]).

OLIGODENDROCYTES
----------------

Oligodendrocytes are the myelinating cells of the brain, and form an insulating myelin sheath around the axonal segments of neurons. Like astrocytes, oligodendrocytes are of ectodermal origin; they arise from the neural stem cells in the neuroepithelium during early embryogenesis. The onset of myelination, as well as the selection of axons that require myelination, are both tightly regulated. Neuronal activity and degree of differentiation, together with several surface receptors (e.g., LINGO-1), influence the brain area and specific axons that are myelinated ([@B10]; [@B19]). As oligodendrocytes have only a short time window wherein they are capable of myelination, this provides temporal control during early differentiation as well ([@B10]). A single oligodendrocyte can enwrap multiple axons, while a single axon can have adjacent myelin sheets belonging to different oligodendrocytes. Myelination of axons is important for a high-speed, reliable conduction of electrical signals between neurons. The myelinated fibers contain small gaps named nodes of Ranvier that are important for the fast signal conduction, so the action potential can jump from node to node. During the peak of myelination, about three times the weight of the oligodendrocyte is produced in myelin each day. Small changes in protein homeostasis will therefore have huge consequences for protein production and quality control, which can result in misfolding and accumulation of proteins and cause dysfunctional oligodendrocytes and eventually demyelination. Illustratively, transgenic rat overexpressing the oligodendrocyte proteolipid protein showed oligodendrocyte apoptosis and dysmyelination ([@B10]; [@B19]). Axons can be remyelinated by new oligodendrocytes arising from the NG2^+^ cells that are stimulated to divide and differentiate by activated microglia and astrocytes. However, the resulting myelin sheath is thinner, possibly due to the lack of stimulating growth factors that were initially secreted by the growing axon. Oligodendrocyte dysfunction is directly detrimental for neuronal function and leads to neurodegeneration in the α-synucleinopathy multiple system atrophy (MSA), but also in multiple sclerosis and other leukodystrophies ([@B10]; [@B67]).

MICROGLIA
---------

Microglia primarily function as the immune cells of the CNS. In contrast to astrocytes and oligodendrocytes, microglia are from mesodermal origin ([@B43]) and are derived from hematopoietic stem cells in the yolk sac early in embryonic development ([@B4]). Although microglia are mostly known for their function in the immune response under disease conditions, they also play an important role in CNS homeostasis. During neuronal development, microglia regulate brain plasticity, by controlling synapses ([@B64]). Next to phagocytizing apoptotic cells and pruning synapses during development, microglia are actively involved in promoting apoptosis, which is also an important aspect of neuronal development ([@B64]). In the adult brain, microglia also phagocytize dead neurons and express several receptors for neurotransmitters, -peptides, and -modulators, thereby sensing (changes in) neuronal activity. Under healthy conditions, microglia have a small nucleus and long, thin, very motile processes, and although called "resting microglia," these cells are constantly monitoring the environment and when dying neurons are detected, microglia become activated. Subsequent phagocytosis is a tightly regulated process involving multiple receptors like CD36, lectin, and integrin receptors ([@B64]).

Next to neuronal damage, invading pathogens are detected and cleaned up by microglia ([@B5]). To recognize and eliminate foreign entities, a variety of pattern recognition receptors are expressed including complement receptor 3 and toll-like receptors (TLR) 2, 4, and 9 that promote phagocytosis and recognize bacterial lipopolysaccharide (LPS; TLR2, 4) or DNA (TLR9). These cytokines are secreted by CNS associated macrophages, astrocytes and by other microglia as a paracrine activation mechanism. TNF-α, IL-1, and IFNγ are pro-inflammatory cytokines that activate the immune functions of microglia including phagocytosis, cytokine production and antigen presentation. The immune response is regulated by anti-inflammatory cytokines such as IL-10, TGF-β, which downregulate the expression of proinflammatory cytokines, reactive oxygen species (ROS), chemokines and other molecules associated with phagocytosis in microglia ([@B5]; [@B133]).

GLIA IN PATHOLOGY
=================

Early pathological studies showed astrogliosis and microglial proliferation in damaged brain tissues in several neurodegenerative diseases including Huntington's disease (HD; [@B40]), Alzheimer's disease (AD; [@B121]; [@B96]), but also in inflammatory diseases, brain trauma, ischemia and infection ([@B48]; [@B133]; [@B6]; [@B103]). Since microglia sense neuronal damage, they might be the initiators of the glial reaction to neuronal pathology, which is called neuroinflammation (reactive gliosis). Activated microglia have been shown to secrete cytokines that induce astrocyte reactivity. This is a delayed reaction; microglia are sensitive for the smallest pathological changes in the CNS, but only when the damage is severe enough this will lead to astrogliosis. Astrogliosis is characterized by increased expression of the astrocyte-specific intermediate filament GFAP ([@B103]) and vimentin ([@B101]). Astrocytes express cytokine receptors for, e.g., IL-1, IL-6, and TNF-α, and microglia might disturb normal astrocyte function by activating astrocytes via these receptors. For example, TNF-α affects glutamate transmission directly by inhibiting expression of astrocytic glutamate transporters ([@B31]). As a result of activation, astrocytes release cytokines that can in turn influence microglial function ([@B6]). Hereby a feedback loop is created, in which factors from both astrocytes and microglia regulate each other ([@B157]).

It is unclear whether glial activation under pathological circumstances is beneficial or detrimental. Activation of astrocytes is initially meant to protect neurons by forming a protective border around the damaged site ([@B103]), but loss-of-function of astrocytes such as reduced glutamate uptake may also result in neuronal dysfunction ([@B31]). LPS-induced microglial activation is associated with subsequent astrocyte and oligondendrocyte impairment and demyelination. LPS induction of microglia caused a decrease in expression in several astrocytic proteins that are important for their normal function (e.g., Aqp4, a water transport channel). Astrocytes connect to each other and to oligodendrocytes via gap junctions, and activated astrocytes show reduced expression of connexins (30 and 43) that mediate these junctions. As ions, water and osmolites are exchanged via these connexins, loss of this connection leads to decreased oligodendrocyte function and subsequent demyelination and neuronal impairment ([@B120]). In astrocytes, Dicer ablation causes changes in the transcriptome resulting in the upregulation of many immature/reactive astrocyte genes, while astrocytic genes related to mature astrocyte functions are downregulated (e.g., GLT-1). The alterations in astrocyte phenotype occur already before neuronal deficits were perceived, underlining the importance of proper astrocyte function in the brain ([@B137]).

A DIVERGENCE IN UPS BETWEEN NEURONS AND GLIA
============================================

Since glia are essential for proper neuronal function, disturbances in glial function can lead to excitotoxicity and neurodegeneration. However, in neurodegenerative diseases with protein inclusions (proteinopathies), neurons appear to be most vulnerable, as protein aggregation and cell degeneration is mainly observed in neurons. Possibly these differences are due to dissimilarities in their protein homeostasis. Indeed, distinct cell types show divergent protein synthesis and degradation ([@B150]). In addition, differences may exist in UPS levels and activity between neurons and the various glial cells. The UPS is the main protein complex involved in the degradation of oxidized proteins, and oxidation of nucleic acids, lipids and proteins is associated with aging and neurodegenerative diseases ([@B83]). Proteasome inhibition causes an increase in nucleic acid oxidation in both primary neurons and astrocytes; however, this increase is much larger in neurons. This suggests that neurons are more sensitive to proteasome inhibition, or are more prone to oxidative stress, which is associated with neurodegenerative diseases like AD and Parkinson's disease (PD; [@B37]). The UPS appears to be less active in neurons in comparison to white matter glia ([@B146]). Intriguingly, in response to cytokines such as TNF-α, IL-2, G-CSF, and IFNγ, neurons upregulate the Ub-like protein ubiquitin D (or Fat10; [@B77]), which is able to target long-lived proteins to the proteasome. Conversely, both astrocytes and microglia failed to upregulate Fat10 upon cytokine stimulation ([@B55]), also indicating that the UPS is regulated in neurons in another way. In contrast to most other neurodegenerative diseases, in intranuclear inclusion body disease (INIBD) the largest proportion of aggregates are found in glial cells (about 5% in glial cells, compared to 1% in neurons). Here, most aggregates are present in astrocytes, and a smaller proportion in oligodendrocytes. All aggregates are positive for Ub, however, glial cells seem to have a significantly smaller proportion of aggregates positive for the Ub-like proteins NEDD8, NUB1, and SUMO1 than neurons. This slightly dissimilar composition of the aggregates can be explained by either variations in protein expression or protein recruitment toward the aggregates in the cell types ([@B95]). In conclusion, neurons and glia are differently reacting to proteasome inhibition and cytokines. Besides, presence of UPS components in inclusion bodies seem to diverge between neurons and glia, which could be indications why neurons are more vulnerable in neurodegenerative diseases.

UPS IN GLIA IN RELATION TO NEURODEGENERATIVE DISEASES
=====================================================

The tight balance between protein synthesis and degradation is essential for cellular function. In the brain, disturbances in either of the two cause the accumulation and aggregation of short-lived and misfolded proteins. In aging neurons, UPS activity has been shown to be decreased ([@B146]), accordingly, age-related alterations in proteasomal activity are implicated in various neurodegenerative diseases ([@B146]; [@B138]; [@B76]; [@B99]). It remains to be examined in more detail whether and how proteasome levels and activity differ between neurons and glia, which would obviously affect the capacity of cells to maintain proper protein homeostasis. In many diseases protein aggregates are hallmarks that are clearly visible in neurons, and are indicative for neuronal dysfunction. However, aggregates are also described in glial cells, for example in HD ([@B122]; [@B141]) and amyotrophic lateral sclerosis (ALS; [@B22]), although they are usually smaller or less abundant. The discrepancy between the occurrence of neuronal and glial inclusions implies that the UPS system is more efficient to remove aggregation-prone proteins in glia. Yet, while glia might be better able to handle these proteins, this does not mean that glia are not affected. Mainly astrocytes and microglia react to the increase of aggregated proteins in the brain and show altered function, thereby contributing to neuronal dysfunction. Many studies have shown that neuronal UPS dysfunction plays an important role in several neurodegenerative diseases. The first indications were found already more than 25 years ago, when components of the UPS were found in inclusions of several neurological diseases including PD, Pick's disease but also in Rosenthal fibers in astrocytomas ([@B79]). Depletion of 26S proteasome in mice neurons led to significant neurodegeneration and inclusion body formation ([@B12]). Although the depletion was restricted to neurons, changes in glia were observed as astrocytes showed an increase in GFAP and vimentin protein expression, indicative of reactive gliosis ([@B38]). Interestingly, astrocytes themselves seem to be less sensitive for proteasome inhibition. It has recently been suggested that this is due to the high expression of the heat shock protein HSP25 ([@B45]). Although inhibition of proteasomes by the reversible proteasome inhibitor MG-132 caused aggresome formation and cytoskeletal disturbances in cultured primary astrocytes, cell viability was only diminished by 20%. Besides, cytoskeletal disturbances appeared to be reversible in astrocytes, whereas in oligodendrocytes proteasome inhibition massively induced apoptosis. This effect might be caused by the induction of the HSP25, which is expressed at a much higher level in astrocytes and interacts with all three types of cytoskeletal filaments in astrocytes. As downregulation of this protein indeed resulted in fragmentation of actin networks, these results suggest a protective role of HSP25 in the astrocyte cytoskeleton during proteasome inhibition ([@B45]). Proteasome inhibition does not only change cell viability, it has also been shown to decrease intermediate filament transcription in astrocyte cell lines. Treatment with proteasome inhibitors epoxomicin and MG-132 decreased the mRNA levels of the astrocyte-specific intermediate filament GFAP in different astrocyte cell lines. Similarly, vimentin and nestin expression were significantly decreased upon proteasome inhibition in astrocytes, but not in neuronal cells. Moreover, rat brains treated with proteasome inhibitors through a cannula showed less astrogliosis around the cannula. It appeared that the proteasome can affect GFAP promotor activity by the degradation of its transcription factors, thereby linking UPS activity directly to astrogliosis ([@B88]).

Cultured primary oligodendrocytes seem to be much more sensitive to proteasome inhibition when compared to astrocytes. Treatment of these cells with MG-132 caused oxidative stress, mitochondrial dysfunction and apoptosis after 18 h ([@B46]). While inhibition of the 26S regulatory subunit 7 (RPT1, part of 19S) specifically reduced pro-inflammatory cytokine secretion in LPS-stimulated cultured microglia ([@B16]), in general also microglia showed a decreased survival and an increase in pro-inflammatory response following proteasome inhibition, including upregulation of nitric oxide and TNF-α secretion ([@B69]). LPS induction also triggers the secretion of these cytokines by microglia, while intracellularly the pro-inflammatory NF-κB pathway is upregulated. This process is controlled by UPS components, with E3 ligase RING finger protein 11 (RNF11) as one of the key negative regulators of the NF-κB pathway in microglia ([@B32]). In neurons and microglia, IFNγ caused induction of the immunoproteasome by replacing the constitutive subunits β1, β2, and β5 with the inducible immuno subunits β1i, β2i, and β5i and the association with the regulatory complex PA28αβ. Synergistically, LPS-induced neuroinflammation can aggravate neurodegeneration that is triggered by proteasome inhibition ([@B131]; [@B106]).

Since both proteasome inhibition and neuroinflammation are associated with neurodegenerative diseases, studying the interplay between those two will provide new insights in neurodegenerative disease mechanisms. In the following section, proteasome dysfunction and its effect on glia in several age-related neurodegenerative diseases are described and in **Table [1](#T1){ref-type="table"}** an overview of the literature on a wider range of neurodegenerative diseases is given.

###### 

Overview of published data on the role of glia and the UPS in several neurodegenerative diseases.

  Disease                                           Aggregation in glia                                                                                                          UPS changes
  ------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------
  Alzheimer's disease and other tauopathies         Tau in astrocytes and oligodendrocytes ([@B41])                                                                              Immunoproteasome induction in astrocytes and microglia ([@B92]; [@B98]; [@B99])
  Huntington's disease                              Htt in astrocytes ([@B122]; [@B146]; [@B141])                                                                                Immunoproteasome induction in neurons ([@B35])
  Parkinson's disease and other α-synucleopathies   α-syn in oligodendrocytes and possibly astrocytes ([@B23]; [@B130]; [@B102])                                                 No changes
  Amyotrophic lateral sclerosis                     SOD1 and C9orf72 in astrocytes, microglia and oligodendrocytes ([@B22]; [@B42]; [@B93])TDP-43 in oligodendrocytes ([@B21])   Immunoproteasome induction in astrocytes, microglia, oligodendrocytes and neurons. ([@B109]; [@B24]; [@B15])TDP-43 aggregates are Ub positive ([@B158])
  Multiple sclerosis                                No aggregates                                                                                                                Immunoproteasome induction in astrocytes, microglia, neurons and lymphocytes ([@B91]; [@B160]; [@B107]; [@B14])
  Alexander's disease                               GFAP and TDP-43 in astrocytes in Rosenthal fibers ([@B20]; [@B25]; [@B129]; [@B151])                                         Impaired proteasome function in astrocytes ([@B136], [@B135])

ALZHEIMER'S DISEASE
-------------------

Alzheimer's disease is the most prevalent form of dementia and is characterized by irreversible memory loss and impaired cognitive functions. Magnetic resonance imaging (MRI) scans of AD patient brains reveal atrophy and an enlargement of the ventricles caused by neuronal shrinkage or cell loss, and loss of (synaptic) connections is thought to be the main contributor to the cognitive and memory impairments ([@B17]). Neuropathological hallmarks of AD are senile plaques and neurofibrillary tangles. Neurofibrillary tangles are formed by the hyperphosphorylated microtubule-associated protein tau and are located mainly inside neurons, while extracellular the senile plaques consist of aggregates formed by the peptide amyloid β (Aβ). Over the last two decades, the concept of a neuroinflammatory involvement in AD has been established. This started in 1986 with the discovery of plaque-associated reactive microglia, and additional studies described the association of both activated microglia and astrocytes with Aβ plaques expressing pro-inflammatory markers ([@B114]; [@B50]; [@B96]). Astrocytes change their phenotype when contacting extracellular Aβ, and their response includes upregulation of glial fibrillary acidic protein (GFAP), vimentin and S100β ([@B50]; [@B61]). In AD, both astrocytes and microglia play an important role in clearance of Aβ plaques ([@B154]; [@B82]; [@B97]). Besides, attenuation of astrocyte activation leads to a higher plaque load and increased microglial activation, probably as a compensatory mechanism ([@B66]). A loss in metabolic function of activated astrocytes worsens the disease, and upregulation of GFAP has been shown to correlate with downregulation of the astrocyte-specific glutamate transporter EAAT2 ([@B125]; [@B156]).

Changes in the UPS pathway have been associated with AD in several studies. Ub is accumulating in both plaques and tangles ([@B28]). Next to the regular Ub protein in the brains of AD and Down syndrome patients, both having the plaque pathology, a unique form of ubiquitin B can be found. This protein originates from a frameshift mutation in the mRNA and leads to a protein with an aberrant C-terminus, called UBB+1. It can be detected in all AD and Down syndrome patients, but in none of the non-demented controls ([@B148]). Because of the absence of the carboxy-terminal Gly-76, UBB+1 cannot ubiquitinate other proteins, but is itself efficiently ubiquitinated. However, the proteasome seems unable to degrade large amounts UBB+1, leading to proteasome inhibition ([@B70]; [@B149]). In addition, UBB+1 expression also changes the immune response in astrocytes upon TNF-α and IFNγ treatment as secretion of the chemokines CCL2 and CXCL8 is increased dramatically. This is probably due to an upregulation of several proteins in the NF-κB and JNK pathways, suggesting that a disruption in the UPS directly influences pro-inflammatory signaling in astrocytes and *vice versa* ([@B26]).

Importantly, alterations in the UPS can influence the degradation of Aβ in both neurons and astrocytes. Although mainly the neuronal viability is affected in response to increasing Aβ levels, also astrocytes showed a similar upregulation in UPS related proteins and a decrease in proteasome activities upon Aβ treatment as neurons ([@B78]). Treatment with Aβ oligomers decreased proteasome activity *in vitro* and in mouse brain lysates, and a lower proteasome activity was also observed in lysates of several brain areas of AD patients ([@B49]; [@B63]; [@B145]; [@B159]). However, these measurements were mainly performed in whole brain homogenates or in (neuronal) cell lines, and may therefore fail to see alterations in immunoproteasome levels and activity in glial cells since that was not investigated in these studies. More recently, it was shown that Aβ treatment led to an increase in proteasome activity in both cultured neurons, astrocytes and microglia. In addition, it was discovered that both mRNA and protein levels of immunoproteasome subunits β5i and β1i were upregulated in reactive astrocytes and microglia around plaques in AD mice and human AD patient material, whereas in AD mice the levels of β2i were similar to controls. Consistently, the activity of all immunoproteasome subunits was increased with increasing plaque load in both AD mice and in post-mortem material of human AD patients ([@B98]; [@B99]). These results are in line with earlier data showing that β1i expression levels in neurons and astrocytes were increased with age, and in the brain areas most affected in AD ([@B92]). While it becomes clear that especially immunoproteasome activity is increased in glia during AD, it remains to be examined whether these changes are beneficial or not.

PARKINSON'S DISEASE
-------------------

Parkinson's disease is after AD the most common neurodegenerative disease with an incidence of 0.3% in the total population. The incidence increases with age leading to 4% of people above the age of 80 suffering from this mostly idiopathic movement disorder ([@B58]; [@B34]). The etiology of the disease is not known, although there are some familial cases caused by mutations in the genes of, e.g., alpha-synuclein (α-syn) and E3 ligase parkin. Also mutations in UCH-L1, a Ub c-terminal hydrolase, have been associated with PD but this finding is controversial ([@B54]). In PD, the dopaminergic neurons in the substantia nigra pars compacta degenerate, which is accompanied with eosinophillic intracytoplasmatic inclusions known as Lewy bodies (LBs) and gliosis. While microgliosis is dominantly present in PD, reactive astrogliosis is virtually absent ([@B90]; [@B147]; [@B52]). Although they do not change their phenotype, astrocytes are affected by α-syn accumulation. Astrocytes are able to take up α-syn released from neurons, and subsequently secrete pro-inflammatory cytokines (TNF-α and CXCL1), thereby activating microglia ([@B71]). These results were confirmed in a study using a mouse model expressing α-syn in astrocytes only, which caused similar disease symptoms, astrocyte functional loss and activated microglia. As the pro-inflammatory response of these cells caused neurodegeneration ([@B51]), this suggests that glial dysfunction plays a significant role in the etiology of PD.

A role for the UPS in PD was first described in familial PD when it was discovered that mutations in the protein parkin were associated with familial PD. Parkin functions as a Ub ligase in association with proteasomal degradation ([@B58]). A subset of the mutations in parkin, but also post-translational modifications of the protein, have been shown to cause a loss of function of the E3 ligase, and have been associated with UPS impairment and abrogation of the neuroprotective effects of parkin ([@B144]; [@B155]; [@B3]). In addition, Lewy bodies are mainly composed of α-syn and cytoskeletal proteins, but next to these proteins Lewy bodies contain the UPS related proteins parkin and Ub ([@B123]). Induced mutant α-syn expression was reported to decrease proteasome activity in cultured cells and a decreased proteasome activity was detected in the substantia nigra of PD patients ([@B134]; [@B84]). These findings are in contrast with a study that showed that overall proteasome activity was not decreased in brain regions with Lewy body pathology ([@B140]). The discrepancy between these results can be explained by the technique that was used to measure proteasome activity in these studies. The AMC-peptides are rather non-specific since also other proteases can cleave these peptides, thereby influencing the results. Therefore, the exact role of UPS in PD is still under debate. Cultured parkin knock-out neurons appeared to be more resistant to mild proteasome inhibition than wild type neurons due to upregulation of anti-oxidant scavenger protein glutathione and autophagy-related proteins. In contrast, parkin knock-out glia (mixed population, mainly astrocytes) were more susceptible to epoxomicin-induced cell death than wild type glia, suggesting that parkin dysfunction in PD mainly affects glia. In contrast to neurons, this effect on parkin knock-out glia was associated with lower levels of glutathione, a decreased HSP70 response, and an increase in poly-ubiquitinated proteins, all contributing to glial dysfunction. Besides, conditioned medium of parkin knock-out glia was less neuroprotective. So proteasome inhibition causes glial dysfunction and is therefore possibly the reason for the pathology in Parkin knock-out mice ([@B128]; [@B23]). Correspondingly, proteasome inhibitors had deleterious effects in mice expressing α-syn only in oligodendrocytes. The mice showed motor symptoms and severe degeneration in the nigrostriatal pathway caused by myelin disruption and demyelination in oligodendrocytes that had accumulated α-syn fibrils in their cytoplasm ([@B130]). Overall in PD, inhibition of the UPS system seems to contribute to glial dysfunction, thereby also affecting neuronal function. However, similar to AD the exact mechanism causing proteasome changes and neurodegeneration still needs to be unraveled.

HUNTINGTON'S DISEASE
--------------------

HD is a severe familial neurodegenerative disease typified by chorea (abnormal involuntary limb movements), incoordination, cognitive decline, and behavioral difficulties ([@B152]). The prevalence of this autosomal dominant heritable disease is five to seven affected individuals per 100,000 people in the Western world. HD is characterized by neuronal and glial aggregates, neuronal dysfunction and neurodegeneration, starting in the striatum and the cerebral cortex (corticostriatal pathway). An individual is affected when the polyglutamine (polyQ) repeat present in the disease-related huntingtin (HTT) protein exceed 36--41 glutamines ([@B152]). The encoding CAG repeats are not unique for HD as at least eight other neurodegenerative disorders are caused by a similar polyQ expansion in different proteins. Although the cause is already known for decades, the exact disease mechanism is still unclear. Interestingly, even though every cell in the body expresses the polyQ-expanded proteins, mainly neurons are affected and degenerate ([@B53]). Fragments of the polyQ-expanded HTT are thought to initiate aggregation, and the resulting protein aggregates or inclusion bodies (IB) are an important hallmark of HD. More recently it became clear that these IBs are not necessarily causing neurodegeneration, as the formation of IBs did not correlate with cell death in cultured striatal neurons ([@B116]). The formation of IBs may even be a protection mechanism of the cell to sequester toxic monomers and oligomers, thereby promoting cell survival ([@B8]; [@B143]).

Intriguingly, glial cells hardly show aggregates in HD patient material, while the expanded HTT is also expressed in these cells ([@B122]). Still, neuropathological studies show glial involvement in HD by phagocytosis of dead neurons and activated astrocytes ([@B112]; [@B73]), and the severity of both astrogliosis and microgliosis correlates with disease progression ([@B115]; [@B40]). Increased GFAP expression and activated microglia are already observed in presymptomatic stages in HD patients. With increased aggregation in neurons also the number of activated microglia and astrocytes increases ([@B115]; [@B40]). In addition, both microglial cell lines expressing polyQ-expanded HTT and primary microglia from early postnatal HD mice were strongly impaired in their migration toward chemotactic stimuli, and showed a retarded response to laser-induced brain injury *in vivo* ([@B68]). This suggests that polyQ-expanded HTT expression influences the appearance and function of reactive microglia. Similarly, astrocytes showed a loss of their regulatory functions: in the R6/2 HD mouse model decreased levels of glutamate transporters and glutamate uptake were observed, eventually leading to excitotoxicity ([@B122]). Intriguingly, excitotoxicity also occurred when polyQ-expanded HTT is only expressed in striatal astrocytes but not in neurons ([@B40]; [@B153]). In addition, astrocytes isolated from R6/2 mice suppressed the secretion of the chemokine CCL5/RANTES and of BDNF, which is a growth factor important for neuronal survival, thereby inhibiting the trophic functions of astrocytes ([@B27]). So despite the low abundance of IBs, exclusive expression of polyQ-expanded HTT in astrocytes caused a decrease in glutamate uptake followed by excitotoxicity, neurodegeneration and an age-dependent HD-like phenotype in mice ([@B18]), suggesting a crucial role for astrocytes in HD that is directly affected by polyQ-expanded HTT. As astrocytes and microglia hardly show IB formation in HD and when they appear, they are much smaller in size ([@B122]), differences in HTT ubiquitination or proteasome activity might explain these dissimilarities.

An important role for the UPS in HD was suggested in the late nineties, when Ub and proteasomes were found to be colocalized with HTT aggregates as shown by immunohistochemistry in HD mice and post-mortem patient material ([@B33]; [@B36]). This led to the hypothesis that components of the UPS were irreversibly sequestered into HTT aggregates, as was also suggested by FRAP studies that showed no fluorescence recovery after photobleaching in fluorescently tagged proteasomes that were present in aggregates ([@B56]). However, we recently showed with fluorescent pulse-chase experiments that proteasomes were exchanged in HTT aggregates but with slower kinetics than it would be detectable by FRAP analysis ([@B117]). This indicates that proteasomes are dynamically recruited into HTT aggregates. Since soluble HTT can be ubiquitinated, HTT can be targeted for proteasomal degradation ([@B139]; [@B59]). However, various studies have reported an impairment of the proteasome system in both HD cell models and in the brain of HD patients ([@B119]; [@B57]). Moreover, impairment of the proteasome causes accumulation of the potentially toxic aggregation-prone N-terminal HTT fragments ([@B74]). Yet, proteasomes are able to degrade polyQ-expanded HTT fragments efficiently and entirely, but only when HTT is efficiently targeted for degradation by ubiquitination ([@B59]). Together these results suggest a crucial role for the UPS in HD pathogenesis.

Cellular stress due to polyQ-expanded HTT in neurons can lead to proteasome subunit changes, as increased levels of the IFNγ-inducible immunoproteasome subunits LMP2 and LMP7 were observed in cortex and striatum of both HD mice and post-mortem HD patient material. Interestingly, this increase was mainly attributed to degenerating neurons ([@B35]), and may be the result of glial cytokine secretion. It is unknown whether glial cells upregulate immunoproteasomes in HD, and whether the induction of the immunoproteasome is beneficial in HD. While these proteasomes are better capable to deal with protein aggregates under oxidative stress ([@B118]), it is unknown whether immunoproteasomes are also better capable to degrade polyQ-expanded HTT fragments. Still, the apparent absence of HTT aggregates in glial cells remains intriguing, and may be explained by observed differences in proteasome activity in wild type mouse brains where glial cells showed increased proteasome activity when compared to neurons. It remains, however, to be examined whether this explains the differences in aggregate size and abundance. Remarkably, when polyQ-expanded HTT was present in R6/2 mice, proteasome activity levels were not altered ([@B146]), although this does not reflect any possible changes in proteasome composition. The latter finding is underscored by a recent study, where it was shown by using proteasome activity-based probes that proteasomes recruited into aggregates were accessible for substrates and remained active. Besides, no differences were observed in overlay proteasome activity between HD and wild type mice ([@B117]). Together, this indicates that the overall activity of the proteasome does not change in HD, although the composition of proteolytic subunits undergoes some alterations. Therefore, studying the role of the UPS in glial cells in HD is of high importance.

AMYOTROPHIC LATERAL SCLEROSIS
-----------------------------

Amyotrophic lateral sclerosis is a late onset, rapidly progressive and ultimately fatal neurological disorder, characterized by muscle weakness and atrophy leading to the inability to control voluntary movements. These symptoms are caused by the loss of motor neurons in the brain and spinal cord. Prevalence is increasing with age from overall 4--6 cases per 100,000 to up to 33 cases per 100,000 in 60--75-year-olds. About 10% of these patients have the familial form of ALS, often caused by mutations in the gene coding for copper-zinc superoxide dismutase (SOD1; [@B80]). Motor neuron degeneration is often preceded by the formation of nuclear inclusions containing ALS associated proteins SOD1, TDP-43. or FUS and are usually also Ub positive ([@B72]; [@B15]). Glial pathology is strongly present in ALS as observed in cell models, mice and post-mortem patient material ([@B2]; [@B105]; [@B39]). Although SOD1 expression in microglia or astrocytes alone is not sufficient to cause ALS phenotype in mice, transplantation of healthy microglia in SOD1 mutated mice slows down disease progression ([@B47]; [@B30]; [@B13]). In addition, SOD1 expression alone in motor neurons does not cause ALS pathology, suggesting that glial function is important in ALS development ([@B108]). Normally, astrocytes are secreting numerous trophic factors, like VEGF and BNDF to promote neuronal survival, and they take up glutamate from the synaptic cleft. However, activated astrocytes in ALS showed disturbances in these functions, eventually leading to excitotoxicity ([@B142]; [@B39]). Recently, it was shown that a mutation in C9orf72 could lead to aggregates in neurons, astrocytes, microglia and oligodendrocytes ([@B93]). Besides, affected astrocytes caused neuronal cell death when co-cultured, suggesting an important role of astrocytes in this disease ([@B87]). Microglia have been shown to secrete IL-1β as a response to purified mutant SOD1 stimulation, which is thus an important pro-inflammatory trigger ([@B85]). Also secretion of several other pro-inflammatory cytokines such as TFN-α, IFNγ, and IL-6 was reported, resulting in (more) activation of astrocytes and microglia ([@B39]).

Similar to the neurodegenerative diseases described above also impairment of several components of the UPS is observed in ALS, which is likely a cause or consequence of the protein aggregates that are widely present ([@B60]; [@B15]). Impairment of the UPS but not of the autophagic pathway led to ALS-like symptoms in mice. Conditional knock-out of the 19S proteasome subunit RPT3 specifically in motor neurons caused accumulation of ALS related proteins (FUS and TDP-43) in these cells, and led to reactive gliosis and motor dysfunction. A knock-out of autophagy associated gene Atg5 only led to accumulations of Ub and p62 in the cytoplasm but not of ALS-related proteins ([@B138]). While impairment of the UPS in motor neurons induced an ALS-like phenotype, immunohistochemical studies showed significantly increased levels of Ub and proteasome subunits in both motor neurons and astrocytes in ALS ([@B7]; [@B86]). This contradictory result could be explained by findings in an ALS mouse model where a decrease in constitutive proteasome and an increase in immunoproteasome levels were observed, which correlated with the glia-mediated inflammatory response. Also the levels of the reactive astrocyte marker GFAP, the microglia marker CD68, and secretion of the cytokine TNF-α were upregulated in the ALS mice in a presymptomatic stage ([@B24]). Motor neurons in ALS also showed an upregulation of PA28αβ which could lead to a decrease in the turnover of ubiquitinated proteins as this requires the 19S activator ([@B15]). However, when mutant SOD1 mice were crossed with β1i/LMP2 knockout mice, the absence of immunoproteasomes *in vivo* could not significantly prevent mutant SOD1-induced disease; as no changes in disease symptoms were observed ([@B109]). So while activated astrocytes and microglia secrete cytokines that result in the induction of immunoproteasomes in both glia and neurons, these changes seem to be not beneficial in the clearance of accumulating SOD1 proteins.

CONCLUDING REMARKS AND FUTURE PERSPECTIVES
==========================================

Studies on the role of the UPS in neurodegenerative disease are mainly focusing on neurons, as these diseases are often considered to be cell autonomous due to the fact that neurons appear to be the most severe affected. Recently, however, the role of glial cells in neurodegenerative diseases is emerging. The fact that glial activation can already be observed in early presymptomatic stages advocates for an important if not crucial role for glial cells in the initiation of these diseases ([@B132]; [@B40]). Glial cells express most of the disease-related proteins, and glial aggregates are observed in some of these neurodegenerative diseases albeit with lower frequencies ([@B22]; [@B122]; [@B141]). In addition, the disease-causing proteins can alter glial function by the induction of secretion of various cytokines. This makes glial cells important players in the various diseases, as the interplay between disease-causing proteins and the altered UPS not only affects glial cell homeostasis, but indirectly also neuronal function. A common hallmark of the here discussed various neurodegenerative diseases is the general downregulation of the constitutive proteasome accompanied by an upregulated immunoproteasome. This is in line with the observed phenotypical alterations that microglia and astrocytes undergo during disease progression, and the resulting pro-inflammatory environment correlates perfectly with the induction of the immunoproteasome. The induced immunoproteasomes may be better able to degrade intracellular protein aggregates, as suggested for protein aggregates that are induced following IFNγ-induced stress ([@B118]). Since IFNγ is secreted by microglia ([@B62]) and is able to activate both microglia and astrocytes in several neurodegenerative diseases ([@B26]; [@B39]), most likely the observed immunoproteasome induction is mediated by microglia. Nevertheless, while immunoproteasomes are directly induced by IFNγ, this cytokine also induces the accumulation of oxidized proteins that may accelerate aggregation and affect protein homeostasis in time. Still, the induced immunoproteasomes appear better capable to degrade polyubiquitinated proteins under these circumstances, and proteolytic activity of immunoproteasomes is higher compared to standard proteasomes ([@B118]). These data suggest that activation of glia and induction of the immunoproteasome may be beneficial for clearing disease-causing proteins.

Yet, similar to chronic activation of glia, it is unknown whether induction of the immunoproteasome is on the long term beneficial or detrimental in neurodegenerative diseases. After all, the increased immunoproteasome induction in these diseases and in aging could also indicate undesirable protein accumulation and chronic inflammation ([@B35]; [@B92]; [@B24]; [@B98]; [@B99]; [@B14]). When the induction of the immunoproteasome is not beneficial in targeting the accumulating proteins, specific inhibitors targeting immunoproteasome subunits could be an efficient therapeutic approach. Although several of these inhibitors are already developed ([@B89]), more insight is required in the exact function of the immunoproteasome in these disorders.

Next to focusing on proteasome activity, for future approaches it is also important to examine which other alterations in the UPS observed in glia can be used as possible therapeutic targets. Although proteasome compositional changes appear in glial cells during disease progression, in general proteasomes stay active and accessible even in cells showing large protein aggregates ([@B146]; [@B9]; [@B99]; [@B117]). Yet, it is unclear whether the diseased proteins are correctly targeted for degradation, as inefficient ubiquitination of mutant and misfolded proteins could explain the observed protein accumulations and neuronal vulnerability. Improved targeting of the disease-causing proteins toward the proteasome by modifying ubiquitination (or with other Ub-like proteins) would increase their degradation and delay onset of disease. It is unknown whether the ubiquitination patterns of the various disease-related proteins in glia and neurons is dissimilar and whether they change during disease progression. Therefore, determining the ubiquitination patterns of these proteins in different stages of disease in both neurons and glia, along with determining the involved specific ubiquitin ligases and DUBs in these cells should lead to the identification of new and more specific therapeutic targets.
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